The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Biological activitySpecific Activity: 0.0015 pmol/min/µg
Assay conditions: 4 mM ATP, 5mM MgCl2 (both required for reaction), 1mM DTT, E1 (0.5 µg), E2 (2.8 µg), Biotinylated Ubiquitin (1 µg) in 50mM Tris pH 7.4.
% . Purity is >65% by SDS-PAGE.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on Dry Ice. Store at -80°C.
pH: 8.00 Constituents: 20% Glycerol, 0.58% Sodium chloride, 0.395% Tris HCl, 0.05% Tween, 0.0462% DTT Note: 104 µg/ml FLAG peptide
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Apoptosis Inhibitor 3
Baculoviral IAP repeat containing 4
Baculoviral IAP Repeat Containing Protein 4
Baculoviral IAP repeat-containing protein 4
E3 ubiquitin-protein ligase XIAP
IAP like protein
Inhibitor of apoptosis protein 3
Inhibitor of Apoptosis X Linked
Mammalian IAP Homologue A
X linked IAP
X linked inhibitor of apoptosis
X linked inhibitor of apoptosis E3 ubiquitin protein ligase
X linked inhibitor of apoptosis protein
X-linked inhibitor of apoptosis protein
FunctionApoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
Involvement in diseaseDefects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
Sequence similaritiesBelongs to the IAP family. Contains 3 BIR repeats. Contains 1 RING-type zinc finger.
DomainThe first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
Post-translational modificationsUbiquitinated and degraded by the proteasome in apoptotic cells. Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.